Literature DB >> 28933791

Response to Hartley et al. and Mullegama et al.

Pranoot Tanpaiboon1, Kimberly A Chapman1.   

Abstract

Entities:  

Year:  2017        PMID： 28933791     DOI： 10.1038/gim.2017.148

Source DB:  PubMed          Journal:  Genet Med        ISSN： 1098-3600            Impact factor:   8.822


× No keyword cloud information.
  4 in total

1.  Outcomes of Diagnostic Exome Sequencing in Patients With Diagnosed or Suspected Autism Spectrum Disorders.

Authors:  Mari Rossi; Dima El-Khechen; Mary Helen Black; Kelly D Farwell Hagman; Sha Tang; Zöe Powis
Journal:  Pediatr Neurol       Date:  2017-02-08       Impact factor: 3.372

2.  Is it time to retire fragile X testing as a first-tier test for developmental delay, intellectual disability, and autism spectrum disorder?

Authors:  Sureni V Mullegama; Steven D Klein; Dzung C Nguyen; Arang Kim; Rebecca Signer; Michelle Fox; Naghmeh Dorrani; Andrea Hendershot; Rebecca Mardach; Robert Suddath; Katrina Dipple; Eric Vilain; Derek A Wong; Joshua L Deignan; Stephen D Cederbaum; Wayne W Grody; Julian A Martinez-Agosto
Journal:  Genet Med       Date:  2017-09-21       Impact factor: 8.822

3.  De novo mutations in moderate or severe intellectual disability.

Authors:  Fadi F Hamdan; Myriam Srour; Jose-Mario Capo-Chichi; Hussein Daoud; Christina Nassif; Lysanne Patry; Christine Massicotte; Amirthagowri Ambalavanan; Dan Spiegelman; Ousmane Diallo; Edouard Henrion; Alexandre Dionne-Laporte; Anne Fougerat; Alexey V Pshezhetsky; Sunita Venkateswaran; Guy A Rouleau; Jacques L Michaud
Journal:  PLoS Genet       Date:  2014-10-30       Impact factor: 5.917

4.  Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions.

Authors:  G Bradley Schaefer; Nancy J Mendelsohn
Journal:  Genet Med       Date:  2013-03-21       Impact factor: 8.822
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.